Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Prostate Cancer Studies Cougar 301 - Zytiga™ Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed to enrollment Cougar 302 - Zytiga™ Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Closed to enrollment Rising PSA - Taxotere® added to Eligard® Phase III study of Taxotere® added to Eligard® as curative for patients with rising PSA prostate cancer Closed to enrollment Extended Access - Zytiga™ Open label study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed to enrollment Rising PSA - Zytiga™ Phase III study of oral Zytiga™ plus prednisone for patients with rising PSA prostate cancer who are receiving hormone therapy Recruiting PROCEED - Provenge® Registry study to collect long term safety data for patients receiving Provenge ® vaccine Recruiting TAK-700 (Orteronel) Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Recruiting Study information link: http://elmpctrials.com/ TAK-700 (Orteronel) Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer previously treated with chemotherapy Recruiting Study information link: http://elmpctrials.com/ Taxotere® Phase III study to evaluate the addition of Taxotere® prior to surgery to improve outcome for patients with newly diagnosed high risk prostate cancer Recruiting TroVax® Phase II study to evaluate the addition of TroVax® vaccination to standard Taxotere® chemotherapy for patients with advanced prostate cancer Recruiting Prostvac® Phase III study vaccination study for patients with advanced prostate cancer who have not yet received treatment with chemotherapy and have no symptoms or minimal symptoms Recruiting Prolia® Phase III study to evaluate Prolia® for patients with prostate cancer taking hormones. Recruiting TAK-700 (Orteronel) Phase II open-label study of oral TAK-700 plus prednisone for patients with advanced prostate cancer Study pending VT-464-CL-001 (testosterone inhibitor) Phase 1/2 study to evaluate the safety of the study drug VT-464(pill) and how it affects patients with prostate cancer. This is the first time the treatment has been tested in people Study pending Zytiga™+/- Genentec GDC Phase II study of GDC + Zytiga™, versus Zytiga™ alone for patients with advanced prostate cancer previously treated with chemotherapy Study pending MDV3100 Study of MDV3100 in prostate cancer patients with rising PSA Study pending Exelixis Cabozantinib Phase III study of cabozantinib for patients with advanced prostate cancer Study pending Oncogenex Custirsen Phase III study of Custirsen added to Jevtana® in patients with advanced prostate cancer Study pending Bladder Cancer Studies Gemcitabine, Cisplatin, and Avastin chemotherapy A Phase II study comparing IV chemotherapy treatments Gemcitabine, Cisplatin, (Gem/Cis) and Avastin to Gemcitabine, Cisplatin only in advanced bladder cancer Recruiting OGX-427-02 added to Gemcitabine + Cisplatin chemotherapy Phase II study of Gemcitabine + Cisplatin chemotherapy with study drug OGX-427-02 for advanced bladder cancer Recruiting Intravesical chemotherapy with Gemcitabine/Mitomycin/Taxotere® Treatment for superficial bladder cancer in which chemotherapy drugs are infused directly into the bladder through a catheter (intravesical) Recruiting Bladder preservation Bladder preservation with chemotherapy prior to surgery, TURBT (transurethral resection of bladder tumor), concurrent radiation + chemotherapy Recruiting Kidney Cancer Studies AVE0005 (veg trap) Phase II study to determine the effects of two different doses of AVE0005 (veg trap) in patients with advanced kidney cancer Sutent® Treatment with Sutent® (pill) prior to surgery/cryosurgery